BETA

30 Amendments of Michèle RIVASI related to 2013/2022(INI)

Amendment 37 #
Motion for a resolution
Recital C
C. whereas the most common healthcare- related adverse events for the patient or his or her unborn or future descendants are healthcare associated infections (HAIs), medication- or medical-device-related events and complications arising during or after surgical operations;
2013/07/18
Committee: ENVI
Amendment 40 #
Motion for a resolution
Recital D
D. whereas it is estimated that between 8% and 12% of patients admitted to hospitals in the EU suffer from adverse events while receiving healthcare, including HAIs, errors during treatment or surgery, problems arising from the failure or inadequate decontamination of medical equipment, errors in diagnosis and failure to act on the results of tests;
2013/07/18
Committee: ENVI
Amendment 44 #
Motion for a resolution
Recital A a (new)
Aa. whereas any natural or legal person has the right to make public or distribute in good faith, and in safety, information on a fact, an item of data or an action, as soon as a lack of knowledge of this fact, this item of data or this action appears to present a danger to public health;
2013/07/18
Committee: ENVI
Amendment 45 #
Motion for a resolution
Recital E
E. whereas some adverse events are the result of risks inherent in necessary operations or courses of medication deemed necessary by healthcare personnel, while others are the result of avoidable medical errors and, shortcomings and failings in the healthcare supply chain;
2013/07/18
Committee: ENVI
Amendment 59 #
Motion for a resolution
Recital H
H. whereas HAIs, which, on average, are acquired by 5% of patients admitted to hospital, are a major public health problem in the Member States and place a heavy burden on limited health service budgets;
2013/07/18
Committee: ENVI
Amendment 61 #
Motion for a resolution
Recital I
I. whereas HAIs can occur as a result of time spent in healthcare establishments or during the provision of any healthcare services, including home-based services (in particular as a result of errors in dosage, errors in packaging the medicine, contamination of medical instruments or equipment);
2013/07/18
Committee: ENVI
Amendment 90 #
Motion for a resolution
Recital K a (new)
Ka. whereas intensive farming policies promote the occurrence of antibiotic resistance, both through the food chain as well as through animal waste entering the water cycle;
2013/07/18
Committee: ENVI
Amendment 102 #
Motion for a resolution
Paragraph 1
1. Welcomes the measures put in place by Member States with the principal aim of improving general patient safety and preducventing the incidence of HAIs;
2013/07/18
Committee: ENVI
Amendment 118 #
Motion for a resolution
Paragraph 10 – introductory part
10. Urges the Commission and the Member States, in particular, to take, or step up, if they are already being implemented:
2013/07/18
Committee: ENVI
Amendment 122 #
Motion for a resolution
Paragraph 10 – indent 2
– education and training measures for healthcare workers, patients and their carers in the area of patient safety;
2013/07/18
Committee: ENVI
Amendment 124 #
Motion for a resolution
Paragraph 10 – indent 4
– measures to encourage research into patient safety, focusing in particular on forms of therapy that offer an alternative to treatment with antibiotics and a response to resistance to antibiotics, including bacteriophage therapy;
2013/07/18
Committee: ENVI
Amendment 130 #
Motion for a resolution
Paragraph 11
11. Urges the Member StatCommission and the relevant EU agencies to introduce, or strengthen if they already exist, centralised arrangements for reporting adverse events – in particular those involving medicines and medical devices – which make it possible to identify those responsible in the event of a breakdown in the chain of care and learn lessons from such breakdowns, and to make those arrangements known to the public and easy to use;
2013/07/18
Committee: ENVI
Amendment 136 #
Motion for a resolution
Paragraph 12
12. Urges the Commission to consider the headline initiatives and, in particular, to determine whether increased involvement on the part of regional and local authoritiestakeholders could be a suitable way of ensuring that the measures and decisions taken are effective;
2013/07/18
Committee: ENVI
Amendment 142 #
Motion for a resolution
Paragraph 14
14. Urges the Member States, the Commission and the relevant EU agencies to use all relevant technological and statistical instrumenttools to describe and analyse adverse events;
2013/07/18
Committee: ENVI
Amendment 145 #
Motion for a resolution
Subheading 5
b) Measures designed to guard against and reduce the number of HAIs
2013/07/18
Committee: ENVI
Amendment 146 #
Motion for a resolution
Paragraph 16 – introductory part
16. Urges the Member States to continue their efforts to implement, if they have not already done so, additional measures to guard against and reduce the number of HAIs, with a view to falling fully into line with the Council’s recommendations, and in particular measures to:
2013/07/18
Committee: ENVI
Amendment 151 #
Motion for a resolution
Paragraph 16 – indent 3
– support research into the prevention and control of HAIs, focusing in particular on forms of therapy that offer an alternative to treatment with antibiotics and a response to antibiotic resistance, including bacteriophage therapy;
2013/07/18
Committee: ENVI
Amendment 156 #
Motion for a resolution
Paragraph 18
18. Calls on the Member States and their delegated partners to make sufficient human, financial and technological resources available to ensure that care provided in the home or in hospital is of the highest possible quality, and urges them, in particular, not to cut the budgets allocatedto allocate adequate budgets to patient safety, a key issue for European healthcare systems at a time of global spending reviews;
2013/07/18
Committee: ENVI
Amendment 161 #
Motion for a resolution
Paragraph 19
19. Calls on the Member States and the Commission to foster, including by means of awareness-raising campaigns, good practices in all areas, in particular all those linked to hygiene (hand hygiene, sterilisation of instruments, etc.and optimum decontamination of medical instruments and devices) both in and outside hospital (in particular vis-à-vis patients and their families);
2013/07/18
Committee: ENVI
Amendment 170 #
Motion for a resolution
Paragraph 21
21. Calls on the Member States to use the most advancedeffective technological means available to guarantee optimum patient safety, and, in particular, to introduce across the board electronic health passports containing all relevant information about the patient, including his or her antecedents;
2013/07/18
Committee: ENVI
Amendment 180 #
Motion for a resolution
Paragraph 22 – indent 3
– the use of throwaway medical equipment that has undergone optimum decontamination, or of throwaway medical equipment where the necessary degree of decontamination cannot be achieved, must be encouraged as far as possible;
2013/07/18
Committee: ENVI
Amendment 187 #
Motion for a resolution
Paragraph 23 a (new)
23a. Calls on the Member States to draw on and accord proper importance to expertise built up as a result of patients’ own experience when compiling best practices;
2013/07/18
Committee: ENVI
Amendment 193 #
Motion for a resolution
Paragraph 25
25. Calls on the Commission, the relevant EU agencies and the Member States to provide patients or their legal representatives with information about risks, safety levels and the measures taken to prevent adverse events in healthcare, in order to ensure that patients or their legal representatives can give informed consent to the treatment they are being offered and, more generally, to enable patients to learn more about the issue of patient safety, and urges them to inform patients about complaints procedures and the legal remedies available to them should adverse events in healthcare occur;
2013/07/18
Committee: ENVI
Amendment 197 #
Motion for a resolution
Paragraph 25 a (new)
25a. Calls on the Member States to guarantee patients and their legal representatives the right to refuse any form of treatment they consider inappropriate, in particular in the light of their age or state of health; points out that this right is intended in particular to protect babies against vaccines containing aluminium and children and pregnant women against treatments containing or releasing endocrine disruptors;
2013/07/18
Committee: ENVI
Amendment 198 #
Motion for a resolution
Paragraph 26 a (new)
26a. Urges the Member States to allow class actions to be brought by patients, their representatives or legal successors in cases where at least two patients are affected by similar healthcare-related adverse events;
2013/07/18
Committee: ENVI
Amendment 206 #
Motion for a resolution
Subheading 9
d) DControl, diagnosis and follow-up
2013/07/18
Committee: ENVI
Amendment 210 #
Motion for a resolution
Paragraph 28
28. Calls on the Commission, the relevant EU agencies and the Member States to encourage the submission of reports and the provision of feedback concerning patient safety not only from medical staff, but also from patients and their relatives;
2013/07/18
Committee: ENVI
Amendment 214 #
Motion for a resolution
Paragraph 29
29. Urges the Commission and the Member States to adopt standardised criteria to identify and monitor places where contamination with HAIs occurs (including facilities outside hospitals) and the ways in which HAIs spread, and to continue their efforts to collect comparable, up-to-date information on general patient safety and HAIs;
2013/07/18
Committee: ENVI
Amendment 222 #
Motion for a resolution
Paragraph 32
32. Calls on the Member States and the Commission to step up cooperation, including with the WHO and the OECD, with a view to standardising measures, definitions, terminology and indicators in the area of patient safety, in particular so as to ensure that high-risk patients may be isolated should a pandemic or cross- border threat emerge;
2013/07/18
Committee: ENVI
Amendment 229 #
Motion for a resolution
Paragraph 35
35. Calls on the Commission, the relevant EU agencies and the Member States to establish and monitor a joint database to be used to compile and make available to the public information concerning adverse events in healthcare, clinical trials of medicines and clinical investigations of medical devices, and to encourage the use of all relevant data collection and alert mechanisms (including those based on confidential declarations);
2013/07/18
Committee: ENVI